🔗 Share this article

While the United States undertakes unprecedented adjustments to its vaccination schedules, a particular individual has surfaced somewhat surprisingly: Høeg, a Danish American sports physician and public health researcher who initially gained attention by casting doubt on Covid shots during the global health crisis and has focused upon potential fatalities after COVID-19 immunization in her recent position at the Food and Drug Administration.

Proposed Shifts to Childhood Vaccine Program

Health officials were set to unveil major changes to the pediatric vaccine schedule in December, aligning the US with Denmark’s national calendar, sources say – a significant shift that would put the US out of step with many the international standard with little proof for improved outcomes. The planned update has been pushed back until the coming year.

Instead of Vinay Prasad, Tracy Beth Høeg is listed to present at the event. She was just designated temporary leader of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to head the division this year.

A New Direction at the Regulatory Body

This interim role could signify a tighter collaboration between the drug and biologics centers as Høeg and Prasad solidify control at the agency – and it points to a greater focus upon reevaluating previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric vaccine recommendations in the US to become more like the Danish model, a society with universal health coverage and a population approximately the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccination policy – usually the domain of Prasad, director of the FDA’s vaccine center – rather than medication approval.

Doubts Over Background

Dr. Høeg has little discernible background in drug development, regulation or management, which has been typical for previous leaders of the biologics center. She has worked at the FDA as a top consultant to the commissioner and CBER since spring.

“It seems she lacks to have the necessary background” for overseeing the drug-regulation department, stated Dr. Jonathan Howard. “She’s never run a randomized controlled trial. She has no expertise in managing a sizeable institution. She lacks background in pharmaceutical oversight.”

Former directors of the center would “understand regulatory frameworks and the science of drug development”, noted Dr. Janet Woodcock. “Clearly, she doesn’t have the sort of resume that former directors who headed the center have had.”

This division has an immense range of responsibilities at the agency, she emphasized.

“The public just pays attention on the new drug program, but the generic program authorizes a multitude of generic drugs. There is also a biosimilars program, over-the-counter program and other areas, and each of these have to be supervised,” she said. “The thing you neglect, that is the part that I always told people is going to come back to haunt you.”

Additionally, a major leadership component to the role, which manages over 5,000 personnel. “It’s a enormous administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Controversial Programs

Regarding questions about Dr. Høeg's fitness for the role and whether this assignment signifies greater collaboration among agency officials on vaccines, a representative responded that the “concerns rely on incorrect presumptions”.

“This background is consistent with the duties of her job,” the official said, noting the time Høeg spent guiding the FDA commissioner on “pharmaceutical safety and oversight research, including predictive safety algorithms and vaccine surveillance”.

In her interim role, Høeg inherits the commissioner’s recently launched fast-track approval initiative, a controversial rapid drug-approval program that allegedly worried her preceding directors. “By what process are these medications being picked for this expedited pathway? Who takes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality happening at the agency right now.”

Broadly speaking, he remarked, “the agency seems to be moving towards more relaxed oversight of most medications, with the exception of vaccines.”

Established Past Work on Vaccines

Concerning vaccines, Dr. Høeg has a more documented, if troubling, history, critics said. She authored a study using non-validated crowd-sourced reports to assess the incidence of myocarditis following Covid vaccination. She advised the Florida surgeon general Dr. Joseph Ladapo, who was said to have changed statistics to imply COVID-19 vaccinations are riskier than they are.

Part of her “desired changes” for the incoming government included altering guidelines for new vaccines and halting “non-essential” immunizations, she remarked after the election on a audio program. At the FDA, Høeg has reportedly proposed excluding adolescent males from receiving Covid vaccinations.

“She is an thorough ideologue who starts off with her beliefs and reverse-engineers to accommodate the data in a highly misleading, untruthful manner,” Dr. Howard said.

Gaining Influence and a “Revenge Tour”

Dr. Høeg joined other contrarians, {like|